Early Data Shows CVGBM Vaccine Is Safe in GBM Trial: ESMO 2024
New clinical trial results, presented at ESMO 2024, show that an investigational mRNA-based vaccine CVGBM is safe and well-tolerated in patient with newly diagnosed MGMT-unmethylated glioblastoma (GBM).